Jack Hidary - Nov 4, 2021 Form 3 Insider Report for Intelligent Medicine Acquisition Corp. (IQMD)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	IQMD	Class B Common Stock							Nov 4, 2021	Class A Common Stock	4.9M		See Footnotes	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	As described in the issuer's registration statement on Form S-1 (File No. 333-260205) (the "Registration Statement") under the heading "Description of Securities--Founder Shares", the shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like) and subject to certain anti-dilution rights and have no expiration date.
F2	Intelligent Medicine Sponsor LLC ("Sponsor") is the record holder of the shares of Class B common stock reported herein. Mr. Simon is a board member of the Sponsor along with Jack D. Hidary, Samir N. Khleif, and Geoffrey S. Ling. Each of Messrs. Simon, Hidary, Khleif, and Ling disclaim beneficial ownership of the reported securities other than to the extent of any pecuniary interest they may have therein, directly or indirectly.
F3	Mr. Hidary has an indirect pecuniary interest in shares of Class B common stock of the issuer through membership interests in the Sponsor, over which Mr. Hidary does not have voting or dispositive control.
F4	The shares of Class B common stock beneficially owned by the Sponsor include up to 675,000 shares subject to forfeiture to the extent the underwriter of the initial public offering of the issuer's securities does not exercise in full its over-allotment option as described in the Registration Statement.